Aligos Therapeutics ALGS

$

9
8
7
6
5
4
3
2
1
0
0
9
8
7
6
5
4
3
2
1
0
0
.
9
8
7
6
5
4
3
2
1
0
0
-$0.43 (-3.19%)Past DayToday's Volume:
9
8
7
6
5
4
3
2
1
0
0
9
8
7
6
5
4
3
2
1
0
0
9
8
7
6
5
4
3
2
1
0
0
,
9
8
7
6
5
4
3
2
1
0
0
9
8
7
6
5
4
3
2
1
0
0
9
8
7
6
5
4
3
2
1
0
0

Relative Strength Index (RSI)

- The Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. It is typically used to identify overbought or oversold conditions in financial markets.

- The RSI is calculated using the following formula:

RSI = 100 - (100 / (1 + RS))

Where RS is the ratio of the average gains to the average losses over a specified period.

- The default time period used is 14 days.

- RSI values range between 0 and 100.

RSI values above 70 are considered overbought (indicating a potentially opportune time to sell)

RSI values below 30 are considered oversold (indicating a potentially opportune time to buy)

RSI is not a perfect indicator and should be used in conjunction with other technical analysis tools, this is for informational purposes only and is not a substitute for professional financial advice.

About

Business overview of Aligos Therapeutics (ALGS)
Aligos Therapeutics Inc is a clinical-stage biopharmaceutical company. It is engaged in developing novel therapeutics to address unmet medical needs in viral and liver diseases, including chronic hepatitis B and coronaviruses, and therapeutics for nonalcoholic steatohepatitis (NASH). The company's pipeline includes ALG-010133, ALG-000184, ALG-020572 and ALG-055009, among others.

Key Insights

Critical company metrics and information

  • Latest Closing Price

    $12.94

  • Market Cap

    $46.43 Million

  • Price-Earnings Ratio

    -4.21

  • Total Outstanding Shares

    3.46 Million Shares

  • Total Employees

    68

  • Dividend

    No dividend

  • IPO Date

    October 16, 2020

  • SIC Description

    Biological Products, (no Disgnostic Substances)

  • Primary Exchange

    NASDAQ

  • Type

    Common Stock

  • Headquarters

    One corporate dr., 2nd floor, South san francisco, CA, 94080

  • Homepage

    https://www.aligos.com

Historical Stock Splits

If you bought 25 shares of ALGS before August 19, 2024, you'd have 1 share today.
Execution DateSplit Amount
August 19, 20241-for-25 (Reverse Split)

Cash Flow Statement

July 1, 2024 to September 30, 2024
MetricValue
Net Cash Flow$-9.71 Million
Net Cash Flow, Continuing$-9.71 Million
Net Cash Flow From Operating Activities, Continuing$-20.10 Million
Net Cash Flow From Operating Activities$-20.10 Million
Net Cash Flow From Investing Activities, Continuing$10.40 Million
Net Cash Flow From Investing Activities$10.40 Million

Income Statement

July 1, 2024 to September 30, 2024
MetricValue
Research and Development$16.77 Million
Operating Income/Loss$-20.13 Million
Basic Earnings Per Share$-3.07
Costs And Expenses$20.42 Million
Preferred Stock Dividends And Other Adjustments$0
Income Tax Expense/Benefit$91,000

Comprehensive Income

July 1, 2024 to September 30, 2024
MetricValue
Other Comprehensive Income/Loss Attributable To Parent$83,000
Comprehensive Income/Loss$-19.18 Million
Comprehensive Income/Loss Attributable To Noncontrolling Interest$0
Comprehensive Income/Loss Attributable To Parent$-19.18 Million
Other Comprehensive Income/Loss$-19.18 Million

Balance Sheet

July 1, 2024 to September 30, 2024
MetricValue
Noncurrent Assets$8.60 Million
Other Current Assets$4.92 Million
Wages$4.41 Million
Liabilities And Equity$88.43 Million
Equity$50.10 Million
Assets$88.43 Million

Historical Dividends

Announcement DatePayment DateRecord DateAmountFrequency
No historical dividends

Recent Headlines From The Web

Latest news, press releases, and media coverage about ALGS from trusted financial sources
    All TickersEarnings CalendarNews ArticlesAbout UsPrivacy & Cookies Info

    ⓒ 2025 Financhle. All Rights Reserved.